Cambrex Wins Third API Development Award at CPhI Worldwide

EAST RUTHERFORD, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) — Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has won the ‘Excellence in Pharma: API Development’ category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Frankfurt on November 5th. This marks the third time that Cambrex has won the category in the past 4 years, having previously won in 2016 and 2017. The Company was also judged ‘highly commended’ in the same category in 2018.
The winning entry, for the company’s crystallization screening and process development service, highlighted a peptide crystallization project bridging the gap between the laboratory and manufacturing plant, providing a controlled, robust and scalable crystallization process.Cambrex’s advanced expertise and innovative approach to peptide crystallization allowed for the delivery of a robust, scalable and transferable process affording effective isolation and batch-to-batch consistency and reducing the cost of the purification and manufacturing process. The development also resulted in a crystalline solid form of the peptide, which showed enhanced physical properties and allowed for improvements to be made in downstream processing.“We thank the judges and our industry peers for this unprecedented third API Development award,” commented Hayley Reece, Executive Director, Technical Services at Cambrex Edinburgh. She added, “This project was undertaken at our Edinburgh site, which is a world-leader in providing solid form development services for drug substance and drug product and where we recently announced a strategic expansion, to enable us to serve more customers in the solid-state screening and crystallization process development market.”Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. The awards celebrate thinkers and creators breaking new ground and strongly advocate companies committed to driving the industry forward.About Cambrex
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.